MERCAPTOPURINE ANHYDROUS
Small molecule targets HPRT1, PPAT via inhibition
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Xaluprine (previously Mercaptopurine Nova Laboratories) | — | 2012-03-09 | europa.eu ↗ |
| Approved | US (FDA) | PURINETHOL | — | 1953-09-11 | fda.gov ↗ |
Trials 99 · started per year
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-02-17 | Celltrion | Results CT-P13 (biosimilar infliximab) is comparable to reference infliximab and adalimumab in highly anticipated real-world UK-wide study celltrion.com ↗
According to the study, immunogenicity is a significant factor in non-remission for both infliximab and adalimumab at week 54 but can be mitigated by the use of immunomodulators, azathioprine, mercaptopurine and methotrexate. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-02-17 | Celltrion | CT-P13 (biosimilar infliximab) is comparable to reference infliximab and adalimumab in highly anticipated real-world UK-wide study celltrion.com ↗ |
| 2003-07-01 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Receives North American Rights to Purinethol® as Part of Glaxosmithkline Settlement tevapharm.com ↗ |
Evidence & citations 20 cited values
Every value below carries the sentence it was read from. 218 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MERCAPTOPURINE ANHYDROUS | ChEMBL registry synonym — accepted as the source's own label CHEMBL1425 ↗ |
| Known as | 6-mercaptopurine | “The delayed-release test drugs are 6-mercaptopurine (at a dose of 40 mg daily) or calcitriol (at a dose of 5 mcg three times a week) versus Purinethol (6-MP at a dose of 1-2...” NCT00287170 ↗60“continuous CT with 6 mercaptopurine (90 mg/m2/d, orally) and methotrexate (15 mg/m2/wk, oral-ly), according to a 2-by-2 factorial design stratified on the initial induction...” NCT00599937 ↗ “Oral 6-mercaptopurine with a starting dose of 25 mg/m2 and upward adjusted in steps of 25 mg/m2 (i.e. 50 or 75 mg/m2) if unacceptable bone-marrox toxicity is not encountered” NCT00816049 ↗ “Standard Chemotherapy (which includes cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, 6-mercaptopurine, etoposide, and cytarabine” NCT03319901 ↗ “Includes vincristine, daunorubicin, cyclophosphamide, pegaspargase, prednisone, dexamethasone, cytarabine, 6-mercaptopurine, and high-dose methotrexate.” NCT07495631 ↗ “The longest treatment phase in both protocols is maintenance therapy, which is composed of 6-Mercaptopurine (6MP) and Methotrexate (MTX).” NCT02912676 ↗ “Maintenance therapy with dose-reduced POMP (6-mercaptopurine, vincristine, methotrexate, and prednisone) was given for 3 years.” PMID 37187201 ↗ May 2023 “Patients randomized to IFX combination therapy will also receive 6-mercaptopurine 1-1.5 mg/kg.” NCT06059989 ↗ “Initial dosage of 6-Mercaptopurine (6-MP) is stratified based on NUDT15 and TPMT genotypes:” NCT07462299 ↗ “6-Mercaptopurine by mouth daily NOTE: Only high risk patients will receive 6-Mercaptopurine” NCT02670707 ↗ “Drug:6-mercaptopurine 60 mg/m2/d，po，d1-d28,during maintenance treatment for 2 years” NCT02042690 ↗ |
| Known as | 6-mercaptopurine monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1425 ↗ |
| Known as | 6MP | “Immunosuppressives, e.g. azathioprine (AZA) and 6-mercaptopurine (6-MP), are important in induction of remission and long term treatment of (ulcerative) colitis and Crohn's...” NCT00521950 ↗18“Efficacy and myelosuppression of azathioprine/6-mercaptopurine (AZA/6-MP) are correlated with the metabolite 6-thioguanine, while the metabolite 6-methylmercaptopurine...” PMID 36730289 ↗ Feb 2023 “The delayed-release test drugs are 6-mercaptopurine (at a dose of 40 mg daily) or calcitriol (at a dose of 5 mcg three times a week) versus Purinethol (6-MP at a dose of 1-2...” NCT00287170 ↗ “The study is designed to evaluate the clinical efficacy and safety of daily treatment for 12 weeks of oral administration of a delayed release, locally delivered 6MP...” NCT01094613 ↗ “The longest treatment phase in both protocols is maintenance therapy, which is composed of 6-Mercaptopurine (6MP) and Methotrexate (MTX).” NCT02912676 ↗ “6-mercaptopurine (6-MP) is a crucial drug in the maintenance phase of acute lymphoblastic leukemia treatment.” NCT06279767 ↗ “Initial dosage of 6-Mercaptopurine (6-MP) is stratified based on NUDT15 and TPMT genotypes:” NCT07462299 ↗ “Mercaptopurine (6MP) is essential to cure childhood acute lymphoblastic leukemia (ALL).” PMID 32519032 ↗ Jun 2020 “a medicine called 6-mercaptopurine or "6MP" is taken by mouth every day at home.” NCT06639958 ↗ “Maintenance therapy 6-Mercaptopurine (6-MP), 50 mg/m2/day orally.” NCT00482833 ↗ “1 x 40 mg Oral Tablet, 6 MP Delayed Release Test Formulation” NCT00774982 ↗ |
| Known as | Mercaptopurina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1425 ↗ |
| Known as | mercaptopurine | “with varied cycles, including Daunorubicin, Vincristine, Prednisone, Pegaspargase, Rituximab, Cytarabine, Mercaptopurine, Cyclophosphamide, Methotrexate, Doxorubicin,...” NCT04845035 ↗157“The study is designed to evaluate the clinical efficacy and safety of daily treatment for 12 weeks of oral administration of a delayed release, locally delivered 6MP...” NCT01094613 ↗ “plus thiopurine (initial dose of azathioprine 2·5 mg/kg or mercaptopurine 1·5 mg/kg, with dose adjustment based on thiopurine metabolite testing)” PMID 34890567 ↗ Dec 2021 “Mercaptopurine (6MP) is essential to cure childhood acute lymphoblastic leukemia (ALL).” PMID 32519032 ↗ Jun 2020 “Maintenance (Methotrexate, Mercaptopurine).” NCT07443592 ↗ “Maintenance (Methotrexate, Mercaptopurine)” NCT04179929 ↗ “Mercaptopurine: 60 mg/m2 po on days 35-59” NCT02396043 ↗ “Melphalan Mercaptopurine Methotrexate” NCT02551718 ↗ |
| Known as | Mercaptopurine hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1425 ↗ |
| Known as | Mercaptopurinum | ChEMBL registry synonym — accepted as the source's own label CHEMBL1425 ↗ |
| Known as | NSC-755 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1425 ↗ |
| Known as | NSC-759614 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1425 ↗ |
| Known as | Puri-Nethol (6-mercaptopurine) | “PuriNethol, Puri-Nethol (6-mercaptopurine)” NCT00816049 ↗ |
| Known as | Purinethol | “Maintenance therapy with dose-reduced POMP (purinethol [6-mercaptopurine], oncovin [vincristine sulfate], methotrexate, and prednisone) was given for 3 years.” PMID 29352703 ↗ Jan 20184“Pharmacokinetics of 50 mg 6MP tablet (Puri-Nethol®) and 20 mg/ml 6MP liquid suspension (Xaluprine®) were compared” PMID 32519032 ↗ Jun 2020 “PuriNethol, Puri-Nethol (6-mercaptopurine)” NCT00816049 ↗ “standard 6MP (100 mg Purinethol)” NCT00774982 ↗ |
| Known as | Purixan | ChEMBL registry synonym — accepted as the source's own label CHEMBL1425 ↗ |
| Known as | Xaluprine | “Pharmacokinetics of 50 mg 6MP tablet (Puri-Nethol®) and 20 mg/ml 6MP liquid suspension (Xaluprine®) were compared” PMID 32519032 ↗ Jun 2020 |
| Known as | Xaluprine (previously mercaptopurine nova laboratories) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1425 ↗ |
| Action | Inhibit | “6-mercaptopurine (6-MP) competes effectively to inhibit HPRT1 activity” NCT06279767 ↗1“Amidophosphoribosyltransferase inhibitor” CHEMBL1425 ↗ |
| Modality | Other / unclassified | “Antineoplastic Agent, Antimetabolite, Immunosuppressant Agent used traditionally to treat Acute lymphoblastic leukemia.” NCT00514982 ↗ |
| Route | Oral | “oral mercaptopurine (MP) once daily” NCT00002514 ↗ |
| Target | HPRT1 | “6-mercaptopurine (6-MP) competes effectively to inhibit HPRT1 activity” NCT06279767 ↗ |
| Target | PPAT | “Amidophosphoribosyltransferase inhibitor” CHEMBL1425 ↗ |